Promise Bio Grant Unlocks Deeper Protein Data for Drug Discovery

NEW YORK, NY – February 23, 2026 – In a move designed to accelerate therapeutic innovation, precision medicine company Promise Bio today launched its Frontier Epiproteomic Innovation Grant. The initiative provides clinical-stage biotech companies with complimentary access to its advanced computational platform, which deciphers the complex world of protein modifications, a layer of biology critical to understanding disease but often beyond the reach of smaller firms.

This R&D access program will grant selected participants comprehensive epiproteomic profiling for up to 200 biological samples. This analysis delves deep into the molecular machinery of cells, detecting up to 64 different types of post-translational modifications (PTMs) that dictate protein behavior. By offering these powerful insights, the company aims to help innovators make more informed, data-driven decisions in their drug development pipelines.

"At Promise Bio, we believe developing breakthrough therapies shouldn't be limited by access to advanced technologies," said Dr. Ronel Veksler, Co-founder and CEO of Promise Bio. "The Epiproteomic Innovation Grant is our commitment to empowering innovators with deep PTM and proteoform insights that are typically out of reach, enabling data-driven R&D decisions to increase the probability of success and ultimately accelerating better outcomes for patients."

Beyond the Genome: The Epiproteomic Frontier

For decades, the fields of genomics and proteomics have provided foundational blueprints for understanding disease. While genomics maps the genetic code, standard proteomics measures the abundance of proteins. However, a crucial layer of biological complexity exists in the epiproteome—the vast landscape of chemical modifications that occur to proteins after they are synthesized. These post-translational modifications act as molecular switches, altering a protein's function, stability, location, and interactions within the cell.

These PTMs and the resulting unique protein versions, known as proteoforms, are often the direct drivers of disease progression, drug response, and the differences seen between patients with the same condition. Yet, studying them has historically been a significant challenge. The sheer number and dynamic nature of PTMs create immense analytical hurdles, often requiring complex, costly, and time-consuming laboratory procedures that are customized for each type of modification. For many research organizations, a broad and deep analysis of the epiproteome has remained an elusive goal.

Promise Bio's technology is designed to overcome this barrier. By applying artificial intelligence and advanced computational algorithms to standard mass-spectrometry data, the platform can perform large-scale PTM profiling without the need for specialized chemical enrichment or additional lab experiments. This approach effectively unlocks a hidden layer of information from data that companies may already possess, providing a more nuanced and functional view of cellular biology.

A New Model for R&D Access

The Frontier Epiproteomic Innovation Grant is more than just a financial award; it represents a new model for democratizing access to cutting-edge technology. The value of the services provided—including comprehensive profiling, quality control, advanced bioinformatics, and expert scientific interpretation for 200 samples—is estimated to be in the tens to hundreds of thousands of dollars. This removes a significant financial barrier for the clinical-stage biotech companies that are often at the forefront of therapeutic innovation but may operate with limited R&D budgets.

Crucially, the program's design emphasizes efficiency. By analyzing existing or newly-generated standard mass-spectrometry data, recipient companies can bypass months of additional wet-lab work. This streamlined workflow allows research teams to rapidly gain deep mechanistic insights, identify novel biomarkers, or develop patient stratification strategies, accelerating critical go/no-go decisions in their clinical programs. The grant targets companies with clearly defined, decision-relevant questions, ensuring the powerful analytical engine is focused on solving concrete problems in drug development.

This strategic initiative also allows Promise Bio to demonstrate the power of its platform on real-world clinical challenges, building a portfolio of case studies that validate its utility in accelerating the path from discovery to clinical success.

Targeting High-Need Disease Areas

The grant is specifically open to clinical-stage biotech companies working in three complex and challenging therapeutic areas: immunology, neurology, and cardio-renal-metabolic (CRM) diseases. These fields are characterized by high patient heterogeneity and complex disease biology, making them prime candidates for the deep insights offered by epiproteomic analysis.

In immunology, PTMs are essential for regulating signaling pathways that control immune cell activation and response. In neurology, abnormal protein modifications are known hallmarks of neurodegenerative diseases like Alzheimer's and Parkinson's. Likewise, in cardio-renal-metabolic disorders such as diabetes and chronic kidney disease, PTMs play a central role in cellular stress and signaling cascades.

By focusing on these areas of high unmet medical need, the grant aims to catalyze progress where it is most needed. Priority will be given to proposals that seek to elucidate a drug's mechanism of action, discover predictive biomarkers for treatment response, or define patient subgroups most likely to benefit from a novel therapy. This focus on translational impact underscores the program's ultimate goal: to help bring more effective, personalized treatments to patients faster.

From Academic Breakthrough to Industry Catalyst

Promise Bio's scientific credibility is anchored in foundational research conducted at the prestigious Weizmann Institute of Science, a world leader in biomedical research. The company's proprietary technology is rooted in work that was featured in the high-impact journal Nature Biotechnology in 2023, highlighting the novelty and significance of its computational approach to PTM analysis.

The company has built upon this academic foundation to create the first cloud-based platform for broad epiproteomics, harnessing the power of AI and scalable computing to transform raw mass-spectrometry data into actionable biological knowledge. This positions Promise Bio not just as a service provider, but as a technology pioneer translating breakthrough science into a tool that can be deployed across the biotechnology industry.

Applications for the Frontier Epiproteomic Innovation Grant are now open, with a submission deadline of April 15, 2026. By equipping innovators with a deeper understanding of disease biology, this initiative holds the potential to reshape drug development strategies and foster a new wave of precision therapies for some of the world's most complex chronic conditions.